Growing trends in the pharmaceutical drug industry are currently pushing toward more accurate and efficient toxicity and side-effect testing through the use of human stem cells. Through the use of induced pluripotent stem cells (iPSCs), companies and researchers can avoid the ethical dilemma of embryonic stem cells while also gaining the advantage of more accurate results in comparison to the cadaver islet and animal based testing that is currently used. Another advantage of the iPSCs that RMS can produce is the ability of these stem cells to provide genetically customized drug treatments to specific patients. This has the potential to revolutionize future treatments of patients with a wide range of diseases.
iPS cells promise to provide new, innovative tools for drug discovery and even greater promise for stem cell therapies. In addition, iPS cells provide great future prospects to make customized, patient-specific stem cell therapy not only possible but available to successfully treat and potentially cure a number of diseases and conditions.
Applications of Pancreatic Cells Derived from Human iPSCs:
- iPSC derived ILC are highly similar to human islets in both function and gene expression, but without the major supply limitation/inconsistency of islets and by virtue of being grown under strict quality control conditions can deliver a consistent product that can be produced on an on-demand basis
- iPS cells can be used to effectively model diseases, such as diabetes, in a dish and allow for greater understanding of the disease itself
- iPS cells can subsequently be applied to pharmaceutical manufacturers and researchers to test the effectiveness or potential toxicity of candidate drugs, thereby making for not only more efficient testing but safer drugs going to the marketplace
- In the future, pancreatic stem cells will be capable of making insulin-producing tissue for transplant purposes. These will be “custom grown” using the patient’s own cells, reducing rejection risk to almost nil.
In the future, pancreatic cells derived from human induced pluripotent stem cells will be capable of making insulin-producing tissue for transplant purposes. These will be “custom grown” using the patient’s own cells, reducing rejection risk to almost nil.